Payload‐free protein nanoparticles target inflamed colons to restore intestinal barrier integrity for effectively treating inflammatory bowel diseases
Authors:
Open Access
Abstract
Anti‐inflammatory compounds, delivered as a payload to the gastrointestinal tract (GIT) by carriers, still cannot treat inflammatory bowel diseases without avoiding side effects. Here, we developed payload‐free protein nanoparticles (PNPs) that crossed GIT to retain in the colon and treat colitis by restoring intestinal barrier integrity by modulating gut microbiome and metabolome. Specifically, PNPs, orally administered to mice with acute colitis, reached the colon within three hours. Consequently, PNPs improve gut microbiota dysbiosis to reverse metabolism balance, suppressing the expression of tumor‐necrosis factor α and toll‐like receptor 4 that restores the intestinal barrier integrity. PNPs then ameliorated colon inflammation and attenuated gut microbiota dysbiosis by exerting probiotic effects on gut microbiota, treating colitis in a week more effectively than the clinically often used 5‐aminosalicylic acid without causing undesired side effects. Such PNPs represent safe, sustainable, and cost‐effective therapeutics for treating inflammatory and metabolic diseases by eliminating microbial and metabolomic imbalance.Keywords
Funding Information
- National Natural Science Foundation of China (81911530223)
- National Natural Science Foundation of China (32101095)
- National Key Research and Development Program of China (2023YFF1103900)
This publication has 61 references indexed in Scilit:
- Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitisBiomaterials, 2022
- Metabolic responses and their correlations with phytochelatins in Amaranthus hypochondriacus under cadmium stressEnvironmental Pollution, 2019
- Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitisBiomaterials, 2019
- The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?Current Treatment Options in Gastroenterology, 2019
- Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colonColloids and Surfaces B: Biointerfaces, 2016
- An Integrative View of Microbiome-Host Interactions in Inflammatory Bowel DiseasesCell Host & Microbe, 2015
- Carbachol ameliorates lipopolysaccharide-induced intestinal epithelial tight junction damage by down-regulating NF-κβ and myosin light-chain kinase pathwaysBiochemical and Biophysical Research Communications, 2012
- Synthesis and Characterization of Chitosan Hydrogels Containing 5-Aminosalicylic Acid Nanopendents for Colon: Specific Drug DeliveryJournal of Pharmaceutical Sciences, 2010
- Adverse effects of biologics used for treating IBDBest Practice & Research Clinical Gastroenterology, 2010
- Electrospun silk-BMP-2 scaffolds for bone tissue engineeringBiomaterials, 2006